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Abstract Endothelial cells express S100A4, a metastasis-
associated protein, but its role in angiogenesis remains to be
elucidated. Here we show that knockdown of S100A4 in
mouse endothelial MSS31 cells by murine specific small
interference RNA (mS100A4 siRNA) markedly suppressed
capillary-like tube formation in vitro, in early stage after the
treatment, along with down- and up-regulation of some of the
pro-angiogenic and anti-angiogenic gene expression, respec-
tively. Of particular note is that intra-tumor administration of
the mS100A4 siRNA in a human prostate cancer xenograft
significantly reduced tumor vascularity and resulted in the
inhibition of tumor growth. These findings show that S100A4
in endothelial cells is involved in tube formation, and suggest
its potential as a molecular target for inhibiting tumor angio-
genesis, which warrants further development of endothelial
S100A4-based strategies for cancer treatment.
Keywords Angiogenesis  S100A4  siRNA 
Endothelial cells  Tumor  Therapy
Introduction
S100A4, a member of the S100 family of EF-hand cal-
cium-binding proteins, is involved in the regulation of a
variety of biological processes, including tumor progres-
sion and metastasis [1]. It is highly expressed in various
metastatic tumor cells and its elevated expression is asso-
ciated with the poor prognosis of different types of human
cancers [2–7]. The involvement of S100A4 in the promo-
tion of tumor metastasis has been demonstrated by several
approaches [8–11]. Furthermore, recent studies on mice
that lack the S100A4 gene [12], and on mice carrying
tumor cells subjected to siRNA-mediated S100A4-down-
regulation [13–18], have shown suppression of tumor
development and metastasis formation. Although the pre-
cise mechanism by which S100A4 stimulates invasion and
metastasis remains unknown, an extracellular role for
S100A4 suggested by studies showing the secretion of
S100A4 by cancer cells and the presence of S100A4 in the
serum of cancer patients is intriguing [19]. In fact, the
exogenous addition of S100A4 stimulates endothelial cell
motility in vitro [20] and induces corneal neovasculariza-
tion [19] and metastasis formation in vivo [21]. On the
other hand, little is known about the effect of endothelial
S100A4 on angiogenesis. We previously reported that
S100A4 is expressed in both tumor cells, and endothelial
cells [22, 23]. Although endothelial cells have not been
shown to secrete S100A4, and its biological function in
these cells is unknown, the endothelial S100A4 may be
pertinent for the regulation of tumor angiogenesis and
metastasis, and thus an attractive target for cancer therapy.
In this study, we used siRNA-mediated depletion and
DNA microarray analysis to investigate the function of
S100A4 in endothelial cells. Furthermore, the effect of
S100A4 knockdown on angiogenesis and tumor growth
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was examined in a xenograft cancer model. The results
suggest that S100A4 in endothelial cells is involved in tube
formation and thus siRNA-mediated inhibition of endo-




We cultured mouse endothelial cells (MSS31) [22, 24–26],
human prostate carcinoma cells expressing a firefly lucif-
erase gene (PC-3M-Luc C6, purchased from Caliper Life-
Sciences) [27], mouse melanoma cells (B16-BL6, whose
origin and properties were described by Dr. Fidler [28],
were a gift of Dr. S. Taniguchi, Shinsyu University Grad-
uate School of Medicine) [29] and Lewis lung carcinoma
cells (P29) [30] in DMEM supplemented with 10 % FBS.
siRNA preparation
Synthetic 21-nt RNAs were purchased from Ambion/Life
Technologies (Carlsbad, CA, USA). The murine S100A4
siRNA (mS100A4 siRNA) sequence was 50-UGA ACA
AGA CAG AGC UCA Att-30 (sense) and 50-UUG AGC
UCU GUC UUG UUC Att-30 (antisense). AllStars negative
control siRNA (QIAGEN, Hilden, Germany) was used as a
negative control.
Transfection of siRNA in vitro
After 48 h of siRNA transfection using DharmaFECT No.1
(GE Healthcare, Waukesha, WI, USA), MSS31 cells were
seeded on ECM-gel (SIGMA-Aldrich, St. Louis, MO,
USA) thin-coated center-well dishes (60 mm, BD Falcon,
Franklin Lakes, NJ, USA) at a cell density of 4 9 104 cells/cm2
and cultured in the presence of 50 ng/ml HGF (PeproTech,
Rocky Hill, NJ, USA). Capillary formation was assessed
after 16 h of Matrigel culture [31]. RNA samples were
extracted from transfected cells before seeding for real-
time PCR analysis of S100A4 mRNA, using ISOGEN and
platinum SYBR green qPCR superMix-UDG (Invitrogen/
Life Technologies).
Cell adhesion and wound healing assay
Migration ability was determined using a cell adhesion and
a wound healing assay. After 48 h of S100A4 siRNA or
negative control siRNA transfection, MSS31 cells was
plated on 24-muti-well plate (Nunc, Thermo Scientific,
Japan) at a cell density of 4 9 104 cells/cm2 and then
counted the number of adhered cells at 30 min, 1 and 3 h.
siRNA-transfected MSS31 cells were grown on 60 mm
plates. After the cells reached sub-confluence, the cells
were pretreated with mitomycin C (10 lg/ml) for 30 min
and then the cells were wounded by scraping the mono-
layer and grown in medium for 16 h. The width of the
wound was measured. Three different locations were
visualized and photographed under a phase-contrast
inverted microscope (ECLIPSE1000, Nikon, NY, USA).
Data was represented as a percent of wound healing.
Real-time PCR analysis
Total RNA was extracted from cells by ISOGEN (Nippon
Gene, Tokyo, Japan) and treated with DNase I (Takara,
Otsu, Japan). Five lg of total RNA was used to produce
cDNAs with oligo (dT) 12 primer by superscript III RNA
polymerase (Invitrogen/Life Technologies). cDNA was
diluted five-fold and used for quantitative PCR. For
quantitation, aliquots of 5 ll of cDNA samples were sub-
jected to quantitative PCR in 50 ll reactions using Plati-
num Quantitative PCR SuperMix-UDG (Invitrogen/Life
Technologies) and Assays-on-Demand TaqMan primers/
probe sets (Applied Biosystems, Foster City, CA, USA)
specific for target genes (Supplementary Table S1). Reac-
tions were carried out using the ABI PRISM 7700 sequence
detection System (Applied biosystems). The reactions were
incubated at 50 C for 2 min, then heated to 95 C for
2 min followed by 45 cycles of 30 s at 95 C, 15 s at
60 C, and 20 s at 72 C. The GAPDH gene and b-actin
gene were used as an internal control.
Microarray analysis
RNA quantity and quality were determined using a
Nanodrop ND-1000 spectrophotometer (Thermo Fisher
Scientific Inc., Waltham, MA, USA) and an Agilent Bio-
analyzer (Agilent Technologies, Palo Alto, CA, USA), as
per manufacturer’s instructions. Total RNA was amplified
and labeled with Cyanine 3 (Cy3) using Agilent Low Input
Quick Amp Labeling Kit, one-color (Agilent Technolo-
gies) according to the manufacturer’s instructions. Briefly,
100 ng of total RNA was reversed transcribed to double-
strand cDNA, using a poly dT-T7 promoter primer. Primer,
template RNA and quality-control transcripts of known
concentration and quality were first denatured at 65 C for
10 min, then incubated for 2 h at 40 C with 5X first strand
Buffer, 0.1 M DTT, 10 mM dNTP mix, and AffinityScript
RNase Block Mix. The AffinityScript enzyme was then
inactivated at 70 C for 15 min. cDNA products were used
as templates for in vitro transcription to generate fluores-
cent cRNA. cDNA products were mixed with a transcrip-
tion master mix in the presence of T7 RNA polymerase and
Cy3 labeled-CTP and incubated at 40 C for 2 h. Labeled
18 Angiogenesis (2014) 17:17–26
123
cRNAs were purified using QIAGEN’s RNeasy mini-spin
columns and eluted in 30 ll of nuclease-free water. After
amplification and labeling, cRNA quantity and cyanine
incorporation were determined using a Nanodrop ND-1000
spectrophotometer and an Agilent Bioanalyzer. For each
hybridization, 1.65 lg of Cy3 labeled cRNA was frag-
mented, and hybridized at 65 C for 17 h on an Agilent
Mouse GE 4x44K v2 Microarray (Design ID: 026655).
After washing, microarrays were scanned using an Agilent
DNA microarray scanner. Intensity values of each scanned
feature were quantified using Agilent feature extraction
software version 10.7.3.1, which performs background
subtractions. Features that were flagged as having no errors
(present flags) were used and features that were not posi-
tive, not significant, not uniform, or not above the back-
ground level were excluded. Features that were saturated
and any population outliers (marginal and absent flags)
were also excluded. Normalization was performed using
Agilent GeneSpring GX version 11.0.2. (per chip: nor-
malization to 75 percentile shift; per gene: normalization to
median of all samples). There were 39,429 probes on the
Agilent Mouse GE 4x44K v2 Microarray (Design ID:
026655), excluding control probes. The altered transcripts
were quantified using the comparative method. A C two-
fold change in signal intensity was designated as a signif-
icant difference in gene expression.
Animals
Animal experiments were performed in compliance with
the guidelines of the Institute for Laboratory Animal
Research at the National Cancer Center Research Institute.
The mice were maintained under specific pathogen-free
conditions with a 12-h light–dark cycle.
Study of xenografted tumors
Eight- to 11-week-old male athymic nude mice (CLEA
Japan, Osaka, Japan) were used for all experiments.
Anesthetized animals were subcutaneously injected with
3 9 106 PC-3M-Luc C6 cells in 100 ll sterile Dulbecco’s
PBS [30]. Nine days after subcutaneous inoculation of PC-
3M-Luc C6 cells into mice (hereinafter referred to as day
1), tumors were treated twice with 50 lg siRNA/atelocol-
lagen complex (day 1 and 3). After the treatment, tumor
volume was measured at day 9, 12, and 15. Tumor size was
measured with calipers and tumor volume was calculated
by ab2/2, where a and b are the lengths of the long and
short axes, respectively. Number of animals was 4 in each
group and the experiment was performed twice.
Imaging of tumor angiogenesis
Day 9 after the siRNA treatment, signals of AngioSense-
IVM-750 were measured using fluorescence molecular
tomography (FMT, VisEn Medical/PerkinElmer Inc.,
Waltham, MA, USA). AngioSense-IVM-750 is a 250 kDa
macromolecule that freely circulates while staying con-
fined to the intravascular space. Relative value of angio-
genesis of mS100A4 siRNA-treated tumor was measured
when the negative siRNA control was set to 1.0 and the
data was represented as relative angiogenesis. Blood ves-
sels in tumors monitored by Angiosence day 9 after the
siRNA treatment, tumor vessels were also visualized using
Fig. 1 S100A4 expression in endothelial cells of intratumoral
vessels. B16-BL6 cells were injected subcutaneously into C57BL/6
mice. Two frozen sections of the tumor tissue were double-
immunostained with anti-CD31 antibody (a, d) and anti-S100A4
antibody (b, e). Merged imaged are also shown (c, f). Arrows and
arrowheads in c and f indicate the examples of CD31?S100A4? and
CD31?S100A4- microvessels, respectively. Bars 200 lm
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AngioSense-IVM-680 (ViSen medical) by intravenous
administration of 50 ll per mouse. AngioSense-IVM-680
is a near-infrared labeled fluorescent macromolecule that
remains localized in the vasculature for extended periods of
time and enables imaging of blood vessels and angiogen-
esis. Fifteen min after the dye administration, the vessel
Fig. 2 Anti-angiogenesis activity of S100A4 siRNA in vitro. MSS31
cells were transfected with murine S100A4 siRNA (mS100A4
siRNA) or control siRNA. Two days after transfection, 9.9 9 104
MSS31 cells were seeded on ECM-gel thin-coated center-well dishes.
RNA samples were extracted from transfected cells before seeding for
real-time PCR analysis of S100A4 mRNA. HGF-induced capillary
formation was assessed 16 h after Matrigel culture. a Relative
expression of mS100A4 by real-time PCR analysis. *P = 0.01.
b Western blot analysis of the expression of S100A4 in cells 24 h
after siRNA transfection. Rabbit polyclonal anti-S100A4 antibody
(Abcam, ab27957) and rabbit monoclonal anti-b actin antibody
(Millipore, clone C4/MAB1501) were used. c Tube formation 16 h
after siRNA treatment. Top, untreated control cells; middle, cells
transfected with negative control siRNA; bottom, cells transfected
with mS100A4 siRNA. Scale bars represent 50 lm. d Cell growth
inhibition by mS100A4 siRNA. Cell growth was monitored by cell
number analysis 16 h after siRNA transfection. e Caspase-3/7
activity. The activity was measured 16 h after siRNA transfection
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Fig. 3 S100A4-mediated cell adhesion and migration. a Cell adhe-
sion assay was performed on MSS31 cells treated with S100A4
siRNA or negative control siRNA (N.C. siRNA). Phase-contrast
photograph of adhered cells was recorded at 30 min, 1 and 3 h after
cell plating. Percent of cell adhesion at 30 min was exhibited.
S100A4 siRNA-treated cells: 41 ± 5 %; negative control siRNA-
treated cells: 18 ± 2 %, P = 0.0017. b Wound healing assay was
performed on MSS31 cells treated with S100A4 siRNA or N.C.
siRNA. The width of the wound was measured after 16 h of the cell
wounding by scraping the monolayer. Three different locations were
visualized and photographed under a phase-contrast inverted micro-
scope (ECLIPSE1000, Nikon). Data was represented as a percent of
wound healing. S100A4 siRNA-treated cells: 30 ± 7 %; negative
control siRNA-treated cells: 76 ± 9 %, P = 0.0003
Fig. 4 Inhibition of tumor angiogenesis by mouse S100A4-specific
siRNA (mS100A4 siRNA). a Schematic representation of in vivo
animals experiments. PC-3M-Luc C6 cells (1 9 106 cells) were
subcutaneously inoculated into 9-week-old male athymic nude mice.
Nine days after subcutaneous inoculation of PC-3M-Luc C6 cells into
mice (hereinafter referred to as day 1), tumors were treated twice with
50 lg siRNA/atelocollagen complex (day 1 and 3). Number of
animals in each group was 4. b At day 9, angiogenesis in tumors was
monitored with the administration of the fluorescence detection agent,
AngioSence-IVM-750, by FMT. Photon count per sec of mS100A4
siRNA-treated and the negative control siRNA-treated tumors were
exhibited. The animal experiment was performed twice (N = 4 in
each experiment). *P = 0.05. c At day 9, angiogenesis in tumors
monitored by Angiosence. Vessels were visualized using Angio-
Sense-IVM-680 (ViSen medical) by intravenous administration of
50 ll per mouse. Fifteen min after the dye administration, the vessel
images were acquired by using Olympus OV110 (Olympus, Japan).
Scale bars represent 100 lm
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images were acquired by using Olympus OV110
(Olympus, Japan).
Atelocollagen-mediated siRNA delivery in vivo
To prepare the siRNA/atelocollagen complex, equal
volumes of atelocollagen (1.0 % in PBS at pH 7.4, Koken
Co., Ltd, Tokyo, Japan) and siRNA solution were com-
bined and mixed by rotation for 20 min at 4 C. The final
concentration of atelocollagen was 0.5 %. Individual mice
were injected with 200 ll of atelocollagen containing
50 lg of mS100A4 siRNA or non-silencing control
siRNA/atelocollagen by intratumoral injection (negative
control siRNA).
Measurement of caspase-3/7 activity in vitro
Caspase-3/7, which plays key effector roles in apoptosis,
was determined with the Apo-ONE Homogeneous caspase-
3/7 assay (Promega) according to the manufacturer’s
instructions. Cells were incubated with the Apo-ONE
caspase-3/7 assay reagent for 1.5 h at room temperature,
and the fluorescence was then measured at 485Ex/535Em
with a Wallac multi-label counter.
Double-immunostaining of CD31 and S100A4
B16-BL6 cells (1 9 106 cells) were injected subcutane-
ously into C57BL/6 mice (6–7 weeks of age, Nippon SLC,
Shizuoka, Japan). Fourteen days after the injection, tumor
tissues were removed, embedded in a tissue-freezing
medium, and then cut into 5 lm-thick sections. For double-
immunostaining of CD31 and S100A4, tissue sections were
fixed in acetone for 10 min. The samples were blocked
with PBS containing 0.1 % bovine serum albumin and 2 %
goat serum and then incubated with a mixture of rat anti-
mouse CD31 antibody (Pharmingen, San Diego, CA, USA)
and rabbit anti-S100A4 antibody [23]. The sections were
washed three times with PBS, and incubated with a mixture
of TRITC-labeled goat anti-mouse IgG and FITC-labeled
goat anti-rabbit IgG. After rinsing with PBS, the sections
were mounted in 50 % glycerol in PBS containing 1 mg/ml
p-phenylenediamine to inhibit photobleaching, and were
observed under a confocal laser scanning microscope
(Fluoview, Olympus, Tokyo, Japan). Using NIH Image J
1.42q software (http://rsb.info.nih.gov/ij), a ratio of
S100A4 pixel values to CD31 pixel values was calculated
for each image (n = 6) for determination of S100A4/CD31
double-positive areas.
Statistical analyses
Statistical analyses were conducted using Student’s t test
for in vitro screening of cell capillary morphogenesis and
proliferation and evaluation of in vivo angiogenesis. A
P value of 0.05 or less was considered significant.
Results
Inhibition of capillary formation in endothelial cells
by S100A4 siRNA
We first examined whether endothelial cells of tumor
microvessels express S100A4. For this, we immunostained
the microvessels in tumor tissues formed by B16-BL6
melanoma cells that express little S100A4 with anti-CD31
and anti-S100A4 antibody (Fig. 1, Supplementary Fig. S1).
The results showed that there were S100A4-positive
and -negative CD31? endothelial cells (arrows and
arrowheads in Fig. 1, panels c and f). Quantification of
each S100A4? and CD31? area in double-stained tissue
sections showed that approximately half (49.3 ± 29.5 %,
n = 6) of CD31? endothelial cells was S100A4-positive.
These results suggest that there exist subpopulations of
endothelial cells in tumors that might, or might not, be
primed for angiogenesis. This prompted us to examine the
role of S100A4 in angiogenesis and, to this end, we tested
the effect of siRNA-mediated depletion of S100A4 on
capillary formation in mouse endothelial MSS31 cells.
Specifically, murine S100A4 siRNA (mS100A4 siRNA)
completely blocked S100A4 expression in MSS31 cells at
both the mRNA and protein levels (Fig. 2a, b). Hepatocyte
growth factor (HGF)-induced capillary formation was
assessed 16 h after Matrigel culture [2]. siRNA-induced
knockdown of mS100A4 resulted in the inhibition of HGF-
Fig. 5 mS100A4 siRNA specifically inhibited expression of
mS100A4, but not human S100A4 (hS100A4). MSS31 (murine)
and PC-3M-Luc C6 (human) cells were transfected with murine
S100A4 siRNA (mS100A4 siRNA) and negative control siRNA. Two
days after transfection, RNA samples were extracted from transfected
cells and subjected to real-time PCR analysis of S100A4 mRNA.
*P = 0.05
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induced capillary formation in MSS31 cells in vitro, while
control siRNA showed no inhibitory effect when compared
to untreated controls (Fig. 2c). Additionally, suppression of
cell growth of MSS31 cells was not detectable within 16 h
of mS100A4 siRNA treatment (Fig. 2d) and the analysis of
caspase 3/7 activity did not show caspase-dependent
apoptotic cell death (Fig. 2e), excluding a possibility that
the inhibition of tube formation by the siRNA is non-spe-
cific effect. These results indicate that S100A4 is important
for tube formation of endothelial cells. In addition, cell
adhesion and cell migration assay was performed. As
shown in Fig. 3a, cell adhesion was significantly enhanced
by inhibition of S100A4 by S100A4 siRNA as compared to
N.C. siRNA (P = 0.0017). Wound healing assay revealed
that knockdown of S100A4 inhibited cell migration sig-
nificantly (P = 0.0003) in Fig. 3b. Taken together, these
results of multiple angiogenesis assay clearly indicate that
S100A4 is significantly involved in angiogenesis.
Inhibition of tumor angiogenesis by S100A4 siRNA
To examine the effect of mS100A4 siRNA on tumor
angiogenesis, PC-3M-Luc C6 cells were inoculated into
athymic mice. Nine days after the injection (hereinafter
referred to as day 1), tumors were treated twice with
50 lg siRNA/atelocollagen complex intratumorally. After
the treatment, tumor angiogenesis was measured at day 9
(Fig. 4a). Administration of a fluorescent imaging agent
revealed a strong inhibition of tumor angiogenesis by
mS100A4 siRNA (Fig. 4b), without a discernible reduction
in tumor volume (Supplementary Fig. S3). The mS100A4
siRNA was designed to inhibit specifically murine S100A4
expression, and not human S100A4 in PC-3M-Luc C6 cells
(Fig. 5). Thus, these findings showed that endothelial cells
were the primary targets of mS100A4 siRNA, not human
tumor cells. Additionally, AngioSense analysis demon-
strated that vessel formation in tumors was clearly inhib-
ited by mS100A4 siRNA (Fig. 4c, Supplementary Fig. S2,
Table 1). Thus, the results indicate that mS100A4 siRNA
acts directly upon and inhibits host angiogenesis. We also
found that mS100A4 siRNA inhibits tumor growth, with a
significant reduction in tumor volume by day 15 (Table 2).
Microarray analysis of angiogenesis-related gene
expression in S100A4 knockdown endothelial cells
To gain mechanistic insight into the above observations,
we compared the gene expression profiles of MSS31 cells
treated with either mS100A4 siRNA or control siRNA.
Unsupervised hierarchical cluster analysis was performed
on 745 angiogenesis-related genes (Supplementary
Fig S4,Supplementary Table S1, Supplementary excel file).
The analyses showed that significant alterations in angio-
genesis-related gene expression occurred in the S100A4
siRNA treatment group, suggesting that S100A4 plays a
role in controlling angiogenesis. Genes with significant
alterations (twofold or more) in expression level are listed
in Table 3. These genes were validated by qRT-PCR
analysis (Fig. 6a, b). Genes in mS100A4 knockdown cells
with lower expression levels included angiogenesis-asso-
ciated genes, such as aquaporin-1 (aqp1) [32], fibroblast
growth factor 18 (fgf18) [33], resistin (retn) [34], mitogen-
activated protein kinase kinase kinase 5 (map3k5) [35],
thymus cell antigen (thy1) [36], forkhead box O6 (foxo6)
[37], heparan sulfate 6-O-sulfotransferase 1 (hs6st1) [38]
and matrix metalloproteinase 3 (mmp3) [39], which are
widely expressed in cardiovascular tissue. They induce
endothelial migration and microvessel formation, which
are central to diverse biological phenomena including
angiogenesis, wound healing, and metastasis. Genes in
mS100A4 knockdown cells with higher expression levels
included anti-angiogenesis genes such as cyclin-dependent
Table 1 Area of vessels in animals
Volume of tumor (mm3) Area of vessels (mm2)
Negative control siRNA 36.3 ± 3.1 0.129 ± 0.001
mS100A4 siRNA 31.5 ± 5.0 0.053 ± 0.0008*
Nine days after subcutaneous inoculation of human prostate cancer cells (PC-3M-Luc C6) into mice (hereinafter referred to as day 1), tumors
were treated twice with 50 lg siRNA/atelocollagen complex. After the treatment angiogenesis images were acquired at day 9 using Olympus
OV110 and vessels were visualized using AngioSense-IVM-680 (ViSen medical) by intravenous administration. Area of vessels was measured
by Image J (Olympus). Number of animals was 4 in each group
* P \ 0.05
Table 2 Tumor volume in animals
Volume of tumor (mm3) Day 9 Day 12 Day 15
Negative control siRNA 36.3 ± 3.1 39.7 ± 2.6 44.8 ± 1.8
mS100A4 siRNA 31.5 ± 5.0 30.2 ± 3.8 27.1 ± 2.2*
Nine days after subcutaneous inoculation of human prostate cancer
cells (PC-3M-Luc C6) into mice (hereinafter referred to as day 1),
tumors were treated twice with 50 lg siRNA/atelocollagen complex
twice (day 1 and 3). After the treatment tumor volume was measured
at day 9, 12, and 15. Number of animals was 4 in each group
* P \ 0.05
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kinase inhibitor 1A (cdkn1a) [40], thrombospondin 1
(thbs1) [41], and sprouty homolog 4 (spry4) [42]. Taken
together, microarray analysis validated the function of
endothelial S1004A in angiogenesis.
Discussion
Using B16BL6 tumor tissues little expressing S100A4, we
stained tumor microvessels for CD31 and S100A4 and
found that there are subpopulations of endothelial cells in
tumors, S100A4-positive and –negative ones. This obser-
vation motivated us to examine a possible role of endo-
thelial S100A4 by silencing it. The multiple angiogenesis
assay including tube formation, adhesion, and migration
analysis of endothelial cells clearly indicated that endo-
thelial S100A4 plays a crucial role in angiogenesis.
S100A4-positive endothelial cells in tumors may represent
the ones primed for neoangiogenesis. A comparison of the
gene expression profiles of siRNA-treated cells with those
of untreated cells showed that endothelial S100A4 acts
upstream of a variety of angiogenesis-related genes. These
findings were confirmed in a xenograft tumor model, where
intratumor administration of siRNA distinctly reduced
tumor angiogenesis and growth.
In the present study, mouse siRNA was delivered in vivo
using atelocollagen, a highly purified type I collagen with
low immunogenicity. Atelocollagen forms nano-sized
particles when mixed with oligonucleotides such as double
stranded RNAs and DNAs via electrostatic binding, and is
incorporated into cells by endocytosis [43, 44]. In xeno-
grafted tumor tissues, many cell types can take up the
Table 3 Genes of significant two fold or more alteration of the












Thymus cell antigen thy1 2.1
Forkhead box 06 foxo6 2.1
Heparan sulfate 6-O-sulfotranseferase 1 hs6st1 2.0
Matrix metalloproteinase 3 mmp3 1.7
Upregulated gene
Cyclin-dependent kinase inhibitor 1A cdkn1a 3.2
Thrombospondin 1 thbs1 2.4
Sprouty homolog 4 spry4 2.4
Fig. 6 Modulation of the expression of angiogenesis-related genes
by S100A4 siRNA. Verification of microarray analysis via RT-PCR.
RT-PCR analysis was performed under linear amplification condi-
tions. The GAPDH gene was used as an internal control. a Genes in
mS100A4 knockdown cells with lower expression levels included
angiogenesis-associated genes. b Genes in mS100A4 knockdown
cells with higher expression levels included anti-angiogenesis
genes
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complex, including human prostate cancer cells, endothe-
lial cells and stromal cells. However, the specificity of the
siRNA for mouse S100A4 suggests that the primary target
of the S100A4 siRNA was the mouse vasculature.
Microarray analysis further confirmed the molecular
mechanism of S100A4-mediated angiogenesis in endothe-
lial cells. Significant changes in angiogenesis-promoting
gene expression occurred in S100A4 siRNA-treated endo-
thelial cells. Among the genes exhibiting altered expression
levels, aqp1, map3k5, and fgf18 are highly expressed in
tumor-associated blood vessels in several human tumors
[45–48]. Furthermore, our results indicate that S100A4 may
negatively regulate anti-angiogenic genes, such as cdkn1a,
thbs1, and spry4. This means that S100A4 has a dual effect
on angiogenesis-related gene expression: it up-regulates
angiogenic genes and down-regulates anti-angiogenic ones,
thereby determining the fate of endothelial cells in associ-
ation with tumorigenesis. The biological significance of all
these genes has been proven in vitro and in vivo analysis of
angiogenesis in previous reports.
Our sequential observations revealed that mS100A4
knockdown induced apparent cell growth inhibition of
MSS31 cells in a later stage after siRNA treatment. It
suggests a possible role of S100A4 in regulating endothe-
lial cell growth, which may, in part, account for a drastic
inhibition of neoangiogenesis in mS100A4 siRNA-admin-
istered tumor. Further analysis is required to know whether
S100A4 promotes growth and survival of neovascular
endothelial cells.
In the human cancer xenograft model used in this study,
only host S100A4 was targeted to explore the role of
S100A4 in angiogenesis. However, S100A4 in tumor cells
is also involved in invasion and metastasis. Therefore, it
would be interesting to investigate whether administration
of an agent that inhibits both mouse and human S100A4
could suppress the metastasis of xenografted human tumor
cells in immuno-compromised mice. If suppression occurs,
it would suggest that inhibition of S100A4 could reduce
tumor angiogenesis and by inference, tumor metastatic
ability, which would have important implications for the
development of cancer therapeutics. Furthermore, it would
underscore the advantages of S100A4 inhibition over
conventional angiogenesis factor/receptor inhibition.
Studies are currently under way to develop such agents.
In conclusion, the present results show the importance of
endothelial S100A4 expression in tumor angiogenesis. As
the generation of a new vascular supply is causally
involved in the progression of the majority of solid tumors,
siRNA-mediated inhibition of endothelial S100A4 could
provide an effective anti-tumor RNAi medicine. Thus, the
development of inhibitors targeting endothelial S100A4
could represent a promising approach for effective anti-
angiogenesis and anti-metastasis therapy.
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